PIN1 and prostate carcinoma: This reaction at the key catalytic cysteine leads to an irreversible loss in Pin1 enzyme activity with treatment at high doses, decreasing Pin1 protein levels and suppressing cancer cell proliferation in breast, lung, and prostate cancers (Zeltz et al., 2020; Ghosh et al., 2021).